UBS Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-39,027
| Closed | -$3.98M | – | 10236 |
|
|
2023
Q2 | $3.98M | Buy |
39,027
+21,283
| +120% | +$2.01M | ﹤0.01% | 2810 |
|
|
2023
Q1 | $1.61M | Buy |
17,744
+15,259
| +614% | +$895K | ﹤0.01% | 3652 |
|
|
2022
Q4 | $94.4K | Sell |
2,485
-1,273
| -34% | -$43.8K | ﹤0.01% | 6165 |
|
|
2022
Q3 | $94K | Buy |
3,758
+1,200
| +47% | +$33.3K | ﹤0.01% | 5762 |
|
|
2022
Q2 | $78K | Buy |
2,558
+759
| +42% | +$22.6K | ﹤0.01% | 5606 |
|
|
2022
Q1 | $59K | Sell |
1,799
-1,759
| -49% | -$52.2K | ﹤0.01% | 6341 |
|
|
2021
Q4 | $93K | Sell |
3,558
-2,614
| -42% | -$202K | ﹤0.01% | 6380 |
|
|
2021
Q3 | $621K | Sell |
6,172
-1,207
| -16% | -$141K | ﹤0.01% | 4575 |
|
|
2021
Q2 | $1.04M | Buy |
7,379
+875
| +13% | +$98.8K | ﹤0.01% | 4138 |
|
|
2021
Q1 | $648K | Sell |
6,504
-9,333
| -59% | -$1.09M | ﹤0.01% | 4667 |
|
|
2020
Q4 | $1.96M | Sell |
15,837
-23,506
| -60% | -$3.09M | ﹤0.01% | 3430 |
|
|
2020
Q3 | $3.83M | Buy |
39,343
+28,122
| +251% | +$3.51M | ﹤0.01% | 2443 |
|
|
2020
Q2 | $1.75M | Buy |
11,221
+8,060
| +255% | +$1.23M | ﹤0.01% | 2997 |
|
|
2020
Q1 | $456K | Sell |
3,161
-12,375
| -80% | -$2.39M | ﹤0.01% | 4057 |
|
|
2019
Q4 | $3.18M | Buy |
15,536
+9,581
| +161% | +$1.75M | ﹤0.01% | 3068 |
|
|
2019
Q3 | $479K | Sell |
5,955
-783
| -12% | -$66.4K | ﹤0.01% | 4604 |
|
|
2019
Q2 | $636K | Sell |
6,738
-21,483
| -76% | -$1.85M | ﹤0.01% | 4117 |
|
|
2019
Q1 | $2.41M | Buy |
28,221
+738
| +3% | +$61.3K | ﹤0.01% | 2833 |
|
|
2018
Q4 | $1.54M | Buy |
27,483
+959
| +4% | +$58.5K | ﹤0.01% | 3293 |
|
|
2018
Q3 | $2.17M | Sell |
26,524
-8,521
| -24% | -$601K | ﹤0.01% | 3152 |
|
|
2018
Q2 | $1.23M | Buy |
35,045
+15,112
| +76% | +$460K | ﹤0.01% | 3599 |
|
|
2018
Q1 | $409K | Buy |
19,933
+16,458
| +474% | +$424K | ﹤0.01% | 4335 |
|
|
2017
Q4 | $99K | Buy |
3,475
+1,110
| +47% | +$31K | ﹤0.01% | 5360 |
|
|
2017
Q3 | $73K | Sell |
2,365
-967
| -29% | -$29.1K | ﹤0.01% | 5537 |
|
|
2017
Q2 | $105K | Buy |
3,332
+2,109
| +172% | +$51.9K | ﹤0.01% | 5143 |
|
|
2017
Q1 | $27K | Sell |
1,223
-1,265
| -51% | -$31.2K | ﹤0.01% | 5941 |
|
|
2016
Q4 | $54K | Buy |
+2,488
| New | +$62.9K | ﹤0.01% | 5773 |
|
|
2016
Q3 | – | Sell |
-2,000
| Closed | -$40K | – | 8011 |
|
|
2016
Q2 | $40K | Buy |
+2,000
| New | +$38.9K | ﹤0.01% | 5692 |
|
Other funds holding RETA
UBS Group's RETA Position: Q3 2023 in Review
UBS Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 39,027 shares — an estimated $3.98M sold.
UBS Group first reported a position in RETA in Q2 2016 and held it in 28 quarters. The position peaked at $3.98M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- UBS Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 39,027 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3.98M.
- UBS Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 28 quarters.
- UBS Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.98M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.